Biomedicine "Twelve Five" plan will be announced during the first half.
Yesterday the NDRC website linked to the text, beginning on the "Five-second bio-industry development plan" to seek views of the community. According to the reporter involved in the preparation from a "second Five-Year Plan the development of biological medicine," the authorities at the exclusive that, digital thermometer as a "bio-industry development second Five-Year Plan" of the sub-plan, "the development of biological medicine second Five-Year Plan" will the end of June this year, before the official announcement.
According to the National Development and Reform Commission, the "Five-second bio-industry development plan" clinical thermometer is the twelfth national economic and social development planning system in the five-year special plan, is also being prepared by the "five-second strategic development of new industries planning "one of the supporting special plan.
ear thermometer The article said, the National Development and Reform Commission jointly with relevant departments from the biotechnology industry in the direction of technological innovation, industrialization and industrial development of the main tasks, industrial layout, market cultivation, training, and fiscal policy, investment and financing policies, and many other activities to promote the development of bio-industry related research work. Welcome to the community to actively participate in, offer advice and suggestions on the development of biotechnology industry trends at home and abroad, China to speed up the development of biotechnology industry is facing major problems and countermeasures, digital blood pressure monitor bio-industry development priorities and direction of the views put forward proposals.
Bio-life science industry, including cutting-edge technology, bio-agriculture, bio-pharmaceuticals, industrial biotechnology, bioenergy, environmental biotechnology, biological resources and bio-security research and development. As the most important part of the biotechnology industry, affecting the development of bio-medicine more attention to the eyes, the community also have the planning suggestions.
The end of Eleventh Five-Year, China's biomedical industry has achieved a trillion magnitude scale, compound growth rate of about 20%, but there is structure is irrational, and other outstanding problems can be very inadequate. Transformation of Chinese Medical Science and Technology Center Ruiguo Zhong told reporters.
It was explained that the so-called energy level structure of the development is not a problem, not high profit levels of enterprises, and products in the market share not high.
Therefore, he suggested, during the second five-, bio-pharmaceutical industry on the industrial structure adjustment should be a top priority to maintain the sound development of the industry. At the regional structure, technological structure, economic structure and the sub-sector specific areas such as adjustment of product structure, from national to local government innovation on the biotechnology industry to boot, change the mode of economic growth.
To create a bio-pharmaceutical industry, bio-valley site Alibaba, chairman of Cheung Fat Po, told reporters in R & D, manufacturing, services, capital and other sectors, countries should be some guidance and promotion. The development of biological medicine from abroad, experience, legal and other services to the industry is very important for biomedical services industry, the value created equally astounding.
In addition, capital environment, the Government should also be big investment, big risk, big reward for the biomedical characteristics of the investment projects to boot, such as the establishment of industry funds. ZHANG Fa Bao said. (Shanghai Securities News)
Pharmaceutical sector: the fundamentals supporting the valuation fixed for opportunities
This year, 1 month, continues the pharmaceutical sector in December last year, since the weak trend, down 9.39%, while the Shanghai Composite Index over the same period fell by only 0.62%. Broker that after the oversold bounce there must be, pre-investment in pharmaceutical stocks fell to the Year of the Rabbit to the plate and opportunities.
Industry to benefit from aging, urbanization, new medical reform.
Donghai Securities promising pharmaceutical sector fundamentals. The release of the report:
Rising raw material costs and the economic restructuring and other reasons, the future will be the investment growth era of scarce species.